Pulmonary and activation-regulated chemokine (PARC)/CCL18 is a significant, primarily indirect, modulator of fibrosis and is elevated in association with various fibrotic lung diseases, including scleroderma, hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, asthma, and sarcoidosis. Here, CCL18 is linked to sarcoidosis.